Results 141 to 150 of about 196,807 (276)

In vitro concurrent paclitaxel and radiation of four vulvar squamous cell carcinoma cell lines [PDF]

, 1996
Misa Jaakkola, Virpi Rantanen, Seija Grénman, Jarmo Kulmala, Reidar Grénman   +4 more
openalex   +1 more source

Five‐year outcomes of pembrolizumab versus chemotherapy in Chinese patients with non‐small‐cell lung cancer and programmed cell death ligand 1 tumor proportion score ≥1%: KEYNOTE‐042 China study

International Journal of Cancer, EarlyView.
What's New? Global research has found that for people newly diagnosed with advanced non‐small cell lung cancer (NSCLC), the anti‐PD‐1 monoclonal antibody pembrolizumab on its own often leads to better results than traditional chemotherapy. The present report details long‐term findings of pembrolizumab therapy specifically among Chinese patients.
Yi‐Long Wu, Li Zhang, Yun Fan, JianYing Zhou, Li Zhang, Qing Zhou, Wei Li, ChengPing Hu, GongYan Chen, Xin Zhang, CaiCun Zhou, Carmen González Arenas, Zhenghong Chen, Wen Cheng Yu, Tony S. K. Mok   +14 more
wiley   +1 more source

The ups and downs of paclitaxel-coated balloons and paclitaxel eluting stents: do the conclusions of SWEDEPAD 2 change our practice? Should we be concerned about mortality (again)? [PDF]

CVIR Endovasc
Müller-Hülsbeck S, Fanelli F, Haage P, Hamady M, Kobeiter H, Loffroy R, O'Sullivan G, Ratnam LA, van Rijswijk CSP, Ruffino MA, Wolf F, Morgan RA.   +11 more
europepmc   +1 more source

Short-term Efficacy of Paclitaxel Plus Concurrent Late-course Accelerated Hyperfractionated Radiotherapy on Elderly Patients with Esophageal Carcinoma

, 2011
LI Hong-liang, Zhou Li-qing, Yan Yan, Aiming Yang, Fei Yang   +4 more
openalex   +2 more sources

Data from Combination Paclitaxel and Palbociclib: Results of a Phase I Trial in Advanced Breast Cancer

, 2023
Amy S. Clark, Nicholas P. McAndrew, Andrea B. Troxel, Michaël Feldman, Priti Lal, Mark Rosen, Jessica Burrell, Colleen Redlinger, Maryann Gallagher, Angela R. Bradbury, Susan M. Domchek, Kevin R. Fox, Peter J. O’Dwyer, Angela DeMichele   +13 more
openalex   +1 more source

Treatment landscape from first‐ to third‐line therapy and quality of life data of patients with pancreatic cancer from the prospective German PARAGON (Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer) registry (IKF‐PARAGON study)

International Journal of Cancer, EarlyView.
What's New? Pancreatic cancer often is diagnosed at advanced stages. As a result, treatment regimens frequently are aggressive, with substantial side effects that impact quality of life (QoL). This study examined the treatment landscape, from neoadjuvant therapy to palliative care, in the context of QoL among pancreatic cancer patients in Germany. Most
Thorsten O. Goetze, Salah‐Eddin Al‐Batran, Ruediger Liersch, Lars Scheuer, Thomas Goehler, Ulrich Kaiser, Claudio Denzlinger, Stephan Brandl, Daniel Pink, Jens Uhlig, Michael Maasberg, Maria Loose, Marina Schaaf, Disorn Sookthai, Bianca Zäpf, Claudia Pauligk, Timursah Habibzade, Ralf‐Dieter Hofheinz, Christine Koch, for the AIO Study Group   +19 more
wiley   +1 more source

Inherited Retinal Disease as a Predisposing Factor for Paclitaxel Maculopathy. [PDF]

J Vitreoretin Dis
Meshkin RS, Eliott D, Yuan AE, McKay KM.
europepmc   +1 more source

Supplementary Figures 1-3 from Cosilencing of <i>PKM-2</i> and <i>MDR-1</i> Sensitizes Multidrug-Resistant Ovarian Cancer Cells to Paclitaxel in a Murine Model of Ovarian Cancer

, 2023
Meghna Talekar, Qijun Ouyang, Michael S. Goldberg, Mansoor M. Amiji   +3 more
openalex   +1 more source

Efficacy and safety of fruquintinib combined with albumin‐bound paclitaxel as second‐line therapy for advanced gastric cancer following failure of PD‐1 inhibitor‐containing treatment (TACTIC GC‐01): A phase II single‐arm study

International Journal of Cancer, EarlyView.
What's New? Anti‐angiogenic drugs have shown promising efficacy as a second‐line treatment for advanced gastric cancer. However, it remains unclear how alterations in the tumor microenvironment following first‐line immunotherapy may impact tumor angiogenesis and influence subsequent therapeutic outcomes. This single‐arm study prospectively explored the
Xiaoting Ma, Kai Ou, Xiu Liu, Biyang Cao, Wenwei Yang, Jingyu Lu, Letian Zhang, Qi Wang, Lizhen Gao, Zhichao Jiang, Yongkun Sun, Lin Yang   +11 more
wiley   +1 more source

Meta-analysis of the clinical efficacy of anti-PD-1/L1 + paclitaxel/albumin-paclitaxel + platinum vs. paclitaxel/albumin-paclitaxel + platinum in the treatment of patients with advanced non-small cell lung cancer. [PDF]

Oncol Lett
Li F, Yan S, Liu L.
europepmc   +1 more source